Funded Tech Companies
EpiFrontier Therapeutics
Wondering who provided funding to EpiFrontier Therapeutics? Japan Agency for Medical Research and Development (AMED) put venture money into this biopharmaceutical company.
Company Overview
Company Name
EpiFrontier Therapeutics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Undisclosed
Pennington, NJ Undisclosed
USA
Pennington, NJ Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Company Background Information
Overview
EpiFrontier is developing a differentiated epigenetic modulator designed to safely and robustly increase fetal hemoglobin (HbF). Our lead program targets sickle cell disease, with planned expansion into other hemoglobinopathies, including ß-thalassemia. EpiFrontier is a biotechnology company developing oral therapies for hemoglobinopathies. Our goal is to deliver treatments that are accessible to patients worldwide, including those in regions with limited healthcare resources.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
3/24/2026
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bruce Goldsmith
Chief Operating Officer
Ian Hardy
Company Investors
Browse more funded tech companies:
Share this article
About Our Venture Capital Transactions Database
This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs